The neuroimaging clinical sub-study (also called Insight 46) is a clinical study with the specific aims of identifying brain changes that accompany healthy ageing, and detecting brain changes that might help predict who is at greater risk of developing dementia.
This study involves two clinic visits in London, roughly two years apart. Between June 2015 and December 2017, 502 study members were randomly selected from everyone who attended a clinic visit between 2006 and 2011.
The second wave of tests got underway in January 2018 and involves repeating many of the tests from the first wave. During the clinic visit the study members will be asked about their health, medications and any concerns they have about memory; performed a neurological examination, a walking test and some tests of memory and thinking; and at the end of the first day, will undergo a brain scan.
There is now the option of coming back to clinic for an optional additional half-day of further tests, including a number of cardiovascular measurements (such as an ECG and ultrasound of the heart).
We are working with neurologists from the National Hospital for Neurology and Neurosurgery, and Institute of Neurology at UCL.
In 2017, Prof Nick Fox gave an interview to Lauren Pulling from Neuro Central Editor, where he discussed the study and it's aims. The video of the interview is below.
The Dementias Platform UK (DPUK) published in April 2020 the final report on "Work Package 4 - Amyloid discovery cohort". This detailed the neuroimaging study, summarised the findings and listed the papers which had been published to date. A copy of this document can be found on the DPUK website.
If you have any queries regarding the appointment, please contact the study team on 020 3448 4773.
For more general enquiries, please contact NSHD directly on 0800 952 0249 or 0207 670 5705 or MRCLHA.Enquiries@ucl.ac.uk